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Summary
 
Although thrombopoietin has been shown to promote megakaryocyte (MK) proliferation and
maturation, the exact mechanism and site of platelet formation are not well defined. Studies
have shown that MKs may transmigrate through bone marrow endothelial cells (BMEC), and
release platelets within the sinusoidal space or lung capillaries. In search for chemotactic fac-
tor(s) that may mediate transmigration of MKs, we have discovered that mature polyploid MKs
express the G protein–coupled chemokine receptor CXCR4 (Fusin, LESTR). Therefore, we
explored the possibility that stromal cell–derived factor 1 (SDF-1), the ligand for CXCR4, may
also induce transendothelial migration of mature MKs. SDF-1, but not other CXC or CC
chemokines, was able to mediate MK migration (ED
 
50
 
 5
 
 125 pmol/liter). The MK chemo-
taxis induced by SDF-1 was inhibited by the CXCR4-specific mAb (12G5) and by pertussis
toxin, demonstrating that signaling via the G protein–coupled receptor CXCR4 was necessary
for migration. SDF-1 also induced MKs to migrate through confluent monolayers of BMEC
by increasing the affinity of MKs for BMEC. Activation of BMEC with interleukin 1
 
b
 
 resulted
in a threefold increase in the migration of MKs in response to SDF-1. Neutralizing mAb to the
endothelial-specific adhesion molecule E-selectin blocked the migration of MKs by 50%, sug-
gesting that cellular interaction of MKs with BMEC is critical for the migration of MKs. Light
microscopy and ploidy determination of transmigrated MKs demonstrated predominance of
polyploid MKs. Virtually all platelets generated in the lower chamber also expressed CXCR4.
Platelets formed in the lower chamber were functional and expressed P-selectin (CD62P) in
response to thrombin stimulation. Electron microscopy of the cells that transmigrated through
the BMEC monolayers in response to SDF-1 demonstrated the presence of intact polyploid
MKs as well as MKs in the process of platelet formation. These results suggest that SDF-1 is a
potent chemotactic factor for mature MKs. Expression of CXCR4 may be the critical cellular
signal for transmigration of MKs and platelet formation.
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T
 
he development of megakaryocytes (MKs)
 
1
 
 can be di-
vided into two distinct stages or compartments. The
 
1
 
Abbreviations used in this paper:
 
 BMEC, bone marrow endothelial cell(s);
CB, cord blood; ELC, EBV-induced molecule 1 (EBI-1) ligand chemo-
kine; FBS, fetal bovine serum; bFGF, basic fibroblast growth factor;
ICAM-1, intracellular adhesion molecule 1; KL, Kit ligand; LARC, liver
and activation–regulated chemokine; MCP, monocyte chemotactic pro-
tein; MIP, macrophage-inflammatory protein; MK, megakaryocyte;
NAP-2, neutrophil-activating peptide 2; PF4, platelet factor 4;
RANTES, regulated upon activation, normal T cell expressed and se-
creted; SDF-1, stromal cell–derived factor 1; TARC, thymus and activa-
tion–regulated chemokine; TPO, thrombopoietin; VCAM-1, vascular
cell adhesion molecule 1; VEGF, vascular endothelial growth factor.
 
initial stage of MK development involves sequential prolif-
eration of CD34
 
1
 
 hematopoietic stem cells into rapidly
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proliferating megakaryoblasts. The second phase of MK de-
velopment is comprised of a population of morphologically
identifiable MKs that undergo nuclear endoreplication and
ultimately fragment into functional platelets.
Thrombopoietin (TPO) has been shown not only to reg-
ulate MK proliferation, maturation, and endoreplication
(1, 2), but also to induce platelet formation in vitro (3–5).
However, whether the process of platelet formation in vivo
is also mediated by TPO, alone or in combination with
other factors, is not known (6). Recently it has been shown
that NF-E2 (a hematopoietic specific transcription factor of
erythroid cells and MKs) knockout mice, despite physiologi-
cal levels of TPO and an increased level of MKs, have pro-
found reduction in platelet counts (7, 8), suggesting that final
stages of platelet formation and release may be regulated by
as yet undefined cellular signaling pathways. Furthermore,
bone marrow stromal cells have been shown to inhibit
platelet release, suggesting that MKs may have to exit the
bone marrow microenvironment to release platelets (9).
Several studies have shown that mature polyploid MKs re-
side in close proximity to bone marrow endothelial cells
(BMEC; references 10 and 11). Adherence of MKs to the
bone marrow stromal cell extracellular matrix induces exten-
sion of pseudopodia and final fragmentation into platelet-like
particles (12–16). MKs also express certain adhesion mole-
cules that may enable them to interact with resting as well as
cytokine-activated endothelial cells (17, 18). Electron micro-
scopic analysis of bone marrow biopsy samples has shown that
MKs residing at the subluminal surface of the BMEC are ca-
pable of transmigrating through the BMEC junctions (14,
19). Several lines of evidence suggest that MKs generated in
the bone marrow also have the capacity to travel to the lungs,
where MKs fragment into platelets (20–22). Collectively,
these data suggest that one mechanism whereby mature MKs
release platelets is transmigration through BMEC—releasing
platelets in the sinusoidal space or by stochastic fragmentation
in the lung capillaries.
To date, very few reports have explored the effect of
chemokines on MK trafficking. Chemokines such as plate-
let factor 4 (PF4) and neutrophil-activating peptide 2
(NAP-2) have been shown to have an inhibitory effect on
MK development (23–25). However, there has been no re-
port of a chemokine that may induce transmigration of
MKs. In search for factors that may mediate transendothe-
lial migration of MKs, we have found that mature poly-
ploid MKs express the HIV coreceptor CXCR4. Stromal
cell–derived factor 1 (SDF-1), the chemokine ligand for
CXCR4, has been shown to induce transmigration of lym-
phocytes (26, 27) and CD34
 
1
 
 cells (28, 29). In addition,
mice lacking SDF-1 have profound defects in hematopoi-
esis (30). In this report, we demonstrate that SDF-1, the
ligand for CXCR4, increases the affinity of mature MKs
for BMEC and induces transmigration of MKs through
BMEC monolayers, resulting in augmentation of platelet
release. These data suggest that expression of CXCR4 by
mature MKs may be one of the major signaling pathways
that may induce transmigration of MKs, thus initiating the
process of platelet formation.
 
Materials and Methods
 
Preparation of BMEC Monolayer.
 
Primary BMEC were iso-
lated by a standard method as described previously (31). For
transmigration assays, 5-
 
m
 
m pore transwells covered with conflu-
ent monolayers of BMEC were prepared as described previously
(32). Confluent monolayers of BMEC were cultured on bare
transwells in medium 199 (M199; GIBCO BRL, Gaithersburg,
MD) with 20% fetal bovine serum (FBS; Hyclone, Logan, UT),
or with 20% FBS, 5 ng/ml basic fetal growth factor (bFGF), and
50 ng/ml heparin. Before transmigration assay, the integrity of
the monolayer was confirmed by placing 100 
 
m
 
l medium 199/
20% FBS containing [
 
14
 
C]albumin (American Radiolabeled
Chemicals, St. Louis, MO) on the cells for 6 h and measuring the
amount of radioactivity accumulating in the lower chamber (32).
 
MK Preparation.
 
Mononuclear cells derived from human cord
blood (CB) or G-CSF–mobilized peripheral blood leukopheresis
were separated from whole blood obtained from consenting donors,
by Ficoll-Paque (
 
d
 
 5 
 
1.077 g/ml; Pharmacia Biotech AB, Uppsala,
Sweden). CD34
 
1
 
 progenitor cells were purified from mononuclear
cell preparations using magnetic cell sorting Dyna-beads (Dynal
A.S., Oslo, Norway). CD34
 
1
 
 cells derived from CB were used for
ex vivo expansion of MKs for the transmigration studies. MKs were
ex vivo
 
 
 
expanded with TPO (100 ng/ml) and Kit ligand (KL, 10
ng/ml) from CD34
 
1
 
 cells in Xvivo-20 (BioWhittaker, Walkers-
ville, MD) medium for 14–16 d. The number of CD41a
 
1
 
 and
CD42b
 
1
 
 cells on day 12, generated from ex vivo expansion of CB,
was 57 
 
6 
 
10 and 36 
 
6 
 
4% of total expanding cells, respectively.
 
Transmigration Assay.
 
Ex vivo-expanded MKs were washed
once with HBSS solution and resuspended with fresh Xvivo-20
to a density of 10
 
6
 
 cells/ml. Aliquots of the MK cell suspension
(100 
 
m
 
l) were applied on 5-
 
m
 
m pore transwells, covered with or
without confluent BMEC monolayer, in a 24-well plate (Boyden
chamber; Costar Corp., Cambridge, MA [32]). Immediately, 600 
 
m
 
l
of serum-free chemotactic medium, containing Xvivo-20 with or
without various concentrations of chemokines, or MS5-condi-
tioned medium prepared in Xvivo-20, was then placed in the
lower chamber. After 3 h of incubation in bare transwells or 24 h
in BMEC-covered transwells at 37
 
8
 
C in a CO
 
2
 
 incubator, MKs
floating in the transwell, attached to BMEC, or transmigrated to
the lower chamber were manually counted with a hemacytometer,
and the phenotype was analyzed by two-color flow cytometry.
For migration inhibition studies, MKs were preincubated with
40 
 
m
 
g/ml of mAb to CXCR4 (12G5) for 30 min or with 2.5 
 
m
 
g/ml
pertussis toxin in Xvivo-20 for 90 min, washed once with HBSS,
then placed in bare transwells as described above. For chemotac-
tic versus chemokinetic analysis of SDF-1 function, MKs were
suspended in medium containing the same concentration of SDF-1
as the lower chamber, and placed in bare transwells as described
above. To examine the nature of the interaction between BMEC
and MKs, transmigration through IL-1
 
b
 
–activated BMEC was
inhibited by preincubation with 40 
 
m
 
g/ml of anti–E-selectin
(CD62E), anti–vascular cell adhesion molecule 1 (VCAM-1) or
intercellular adhesion molecule 1 (ICAM-1) mAb, alone or in
combination, in the upper and lower chambers for 15 min.
BMEC monolayers were stimulated with 10 U/ml of IL-1
 
b 
 
for
12–16 h. After removal of the IL-1
 
b
 
, the stimulated BMEC
monolayers were incubated with MKs.
 
Flow Cytometry.
 
A total of 10
 
4
 
–10
 
5
 
 cells were incubated for
30 min at 4
 
8
 
C with the FITC- or PE-conjugated mAb CD41a-
FITC, CD42b-FITC, or CXCR4-PE (clones HIP8, HIP1, and
12G5; PharMingen, San Diego, CA). Isotype-matched antibodies
served as controls (IgG1 and IgG2a, FITC- or PE-conjugated;
PharMingen). BMEC detached by collagenase or MKs grown in 
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suspension were harvested by centrifugation and washed twice
with PBS (pH 7.4). The cells were analyzed using an Elite flow
cytometer (Coulter Corp., Hialeah, FL). For coexpression analy-
sis, an FL-1/FL-2 contour plot was used to calculate the percent-
age of positive cells; a proportion of 1% false positive events was
accepted in the negative control sample. The mean fluorescence
intensity was calculated from the fluorescence histogram and ex-
pressed in arbitrary units.
 
Cell Counts and Cytospin Preparation.
 
Cell numbers and con-
centrations were assessed using a hemacytometer or automated
cell counter (Coulter Corp.). Viability of cells, always 
 
.
 
95%, was
confirmed manually with trypan blue, or by flow cytometry with
propidium iodide staining. Standard cytospin preparations were
stained with Wright-Giemsa. A differential count of at least 100
cells was performed for each cytospin preparation.
 
SDF-1 Binding to MKs.
 
Ex vivo–expanded MK cells derived
from CB (6.3 
 
3
 
 10
 
6
 
 cells per 200 ml) were incubated in PBS
with 
 
125
 
I-labeled SDF-1 in the presence and absence of various
concentrations of unlabeled SDF-1 at room temperature for 30
min. The incubation was terminated by removing aliquots from
the cell suspension and separating cells from buffer by centrifuga-
tion through a silicone/paraffin oil mixture. Nonspecific binding
was determined in the presence of 1 mM unlabeled ligand. The
binding data were curve-fitted with the computer program
IGOR (WaveMetrics, Inc., Lake Oswego, OR) to determine
binding affinity (
 
K
 
d
 
), and Scatchard analysis was used for number
of sites per cell.
 
Cell Cycle Analysis of MKs.
 
Ploidy of nonmigrated and mi-
grated CD41a
 
1
 
 MKs was analyzed by propidium iodide. Mi-
grated and nonmigrated MKs were stained with CD41a-FITC
and fixed overnight in 70% ethanol at 4
 
8
 
C. After staining with 50
 
m
 
g/ml propidium iodide containing 100 U/ml RNase A in PBS
(pH 7.4) Ca
 
2
 
1
 
Mg
 
2
 
1
 
, the MKs were analyzed by flow cytometry
focusing on the FITC-positive gate.
 
Antibodies and Reagents.
 
The chemokines IL-8, monocyte
chemotactic protein (MCP)-1, macrophage-inflammatory protein
(MIP)-1
 
a
 
 and 
 
b
 
, thymus and activation–regulated chemokine
(TARC), MIP-3
 
a 
 
(liver and activation–regulated chemokine
[LARC]), MIP-3
 
b
 
 (EBV-induced molecule 1 [EBI-1] ligand
chemokine [ELC]), SDF-1, and Eotaxin were a gift from Berlex
BioSciences, or were purchased from PeproTech (Rocky Hill,
NJ). Radiolabeled SDF-1, 2,200 Ci/mmol, was from NEN Re-
search Products (Boston, MA). The mAb to CXCR4 (12G5) was
as described (33). Pertussis toxin, heparin, propidium iodide, and
RNase A were from Sigma Chemical Co. (St. Louis, MO). mAbs
to E-selectin, VCAM-1, and ICAM-1 were from R&D Systems.
The MS5 stromal cell line, a rich source of SDF-1, was obtained
by incubating MS5 with serum-free medium Xvivo-20 for 48 h.
 
Electron Microscopy.
 
Electron microscopy was performed on
the migrated MKs and platelets formed in the lower chamber of
the transwell plates. Immediately and 24 h after migration of the
MKs in response to SDF-1, the MKs and generated platelets were
fixed immediately in 2% paraformaldehyde, 0.5% glutaraldehyde.
After dehydration, the samples were embedded for electron mi-
croscopy. 60–70-nm (Silver grade) sections were cut using a dia-
mond knife (Diatome, Fort Washington, PA). Sections were
stained with 0.1% lead citrate and examined using an electron mi-
croscope (model 100CXII; JEOL, Ltd., Tokyo, Japan) at an ac-
celerating voltage of 80 kV.
 
Statistical Analysis.
 
Data are expressed as mean 
 
6
 
 SEM of four
to five independent experiments. To detect differences between
migrating and nonmigrating cells, the 
 
t
 
 test for paired samples was
applied. A
 
 P 
 
value 
 
,
 
0.05 was considered statistically significant.
 
Results
 
CXCR4 Is Expressed on Mature MKs.
 
Human MKs de-
rived from CB were
 
 
 
ex vivo expanded with TPO (100 ng/
ml) and KL (10 ng/ml). The time course of expression of
CXCR4 on ex vivo–expanded MKs was measured by two-
color flow cytometry using PE-conjugated mAb to CXCR4
(CXCR4-PE, 12G5) and FITC-conjugated mAb to various
specific MK markers, including GPIIb/IIIa (CD41a-FITC)
and GPIb (CD42b-FITC). CD41a is expressed on early
megakaryoblasts, and its expression persists with maturation
of MKs. CD42b is another specific MK marker which is
mainly expressed on the mature polyploid MKs.
In the first few days of MK expansion, the number of
CD41a
 
1
 
CXCR4
 
1
 
 cells comprised a very small percentage
of the total CD41a
 
1
 
 population. However, by days 12–16
of expansion, the majority of CD41a
 
1
 
 cells were CXCR4
 
1
 
(
 
n
 
 5 
 
5; Fig. 1 
 
A
 
). Moreover, two-color flow cytometry
with CXCR4-PE and CD42b-FITC revealed that all ma-
ture CD42b
 
1
 
 cells expressed CXCR4 (
 
n
 
 5 
 
5; Fig. 1 
 
B
 
).
These data suggest that CXCR4 is expressed on MKs, and
that its expression is enhanced with maturation of MKs.
The majority of the CD41a and CD42b–negative popula-
tion was comprised of immature CD41a
 
1
 
 MKs and CD15
 
1
 
myeloid progenitor cells.
 
SDF-1 Induces Chemotaxis of MKs.
 
The capacity of SDF-1
to induce transmigration of ex vivo–expanded MKs was ex-
amined in a modified Boyden chamber, using a 5-
 
m
 
m bare
transwell plate. In the absence of SDF-1 in the lower cham-
ber, there was virtually no migration (Fig. 2 
 
A
 
). However,
addition of 200 ng/ml of SDF-1 or SDF-1 containing con-
ditioned medium from the MS5 cell line to the lower cham-
ber resulted in significant migration of CD41a
 
1
 
 MKs. On
average, 20% of MKs added to the upper chamber had mi-
grated through the 5-
 
m
 
m pore within 3 h.
Replacement of SDF-1 with TPO (100 ng/ml), IL-8
(200 ng/ml, CXCR1 ligand), or other CC or CXC
chemokines at 100–200 ng/ml, including MIP-1
 
a
 
 (CCR1
ligand), MIP-1
 
b
 
, RANTES (regulated upon activation,
normal T cell expressed and secreted, CCR5 ligand), MCP-1
(CCR2 ligand), Eotaxin (CCR3 ligand), TARC (CCR4
ligand), MIP-3
 
a
 
 (LARC, CCR6 ligand), MIP-3
 
b
 
 (ELC,
CCR7 ligand), failed to induce migration of MKs (Fig. 2 
 
A
 
).
We and others have shown that MKs express vascular endo-
thelial growth factor (VEGF)R1 (fms-like tyrosine kinase 1
[FLT-1]; reference 34) and c-
 
kit
 
 receptor (35). Both VEGF
and KL have been shown to induce chemotaxis and
chemokinesis of certain hematopoietic cells (36). However,
KL failed to induce migration of CD41a
 
1
 
CXCR4
 
1
 
 MKs
(Fig. 2 
 
A
 
). Furthermore, VEGF failed to induce migration of
MKs (data not shown). In addition, replacement of TPO
with all other known megakaryopoietins, including IL-6,
IL-11, bFGF, and PF4, failed to induce migration of MKs.
These data suggest that among the numerous known
chemokines and megakaryopoietins, only SDF-1 has a sub-
stantial effect on the migration of MKs.
Preincubation of MK cells with the blocking CXCR4
mAb (12G5) was able to block SDF-1–induced chemotaxis 
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(
 
n
 
 5 
 
4,
 
 P ,0.05; Fig. 2 B). 12G5 mAb was also able to
block chemotaxis induced by SDF-1 containing condi-
tioned medium from the stromal cell line MS5 (data not
shown). Addition of the G-coupled protein inhibitor per-
tussis toxin (2.5 mg/ml) completely abrogated the migra-
tion of MKs (n 5 4, P ,0.05; Fig. 2 B). Neutralization of
the SDF-1 gradient by adding SDF-1 (200 ng/ml) to both
upper and lower chambers resulted in inhibition of migra-
tion of MKs, indicating that SDF-1’s predominant action
on MKs is chemotactic rather than chemokinetic (n 5 5).
Decrease in the concentration of SDF-1 to 50 ng/ml in the
upper chamber while keeping the SDF-1 concentration
constant in the lower chamber (200 ng/ml) resulted in re-
covery of 18 6 5% of SDF-1 chemotactic activity (n 5 3).
These results suggest that the physiological activity of SDF-1
may depend on the generation of a gradient secretion of the
chemokine within the bone marrow microenvironment.
Since the extracellular matrix within the bone marrow
microenvironment is enriched with heparinoid molecules,
we explored the possibility that heparin-bound SDF-1
Figure 1. CXCR4 is expressed on mature MKs. CD341 cells isolated from umbilical CB were ex vivo expanded into MKs with TPO and KL. Every
4 d, an aliquot of the expanding MKs was removed, and the number of CD41a1CXCR41 or CD42b1CXCR41 cells was quantified with two-color
flow cytometry (right). (A) Although on days 1–4 of expansion there are very few CD41a1 cells that express CXCR4, by day 8, 40% of the expanding
CD41a1 cells expressed CXCR4. On days 12–16 of expansion, 75% of CD41a1 cells express CXCR4 (n 5 5, P ,0.05). The CD41a2 population is
comprised of immature MKs, immature uncommitted cells, or myeloid progenitor cells. (B) During MK expansion, a small percentage of expanding MKs
express the maturation marker CD42b. Virtually all maturing CD42b1 MKs express CXCR4. Although on day 8 there are very few mature
CD42b1CXCR41 cells, by day 12 a large number of expanding MKs are CD42b1CXCR41 (n 5 5, P ,0.01). The majority of the CD42b2 population
is immature CD41a1 MKs and myeloid progenitor cells.
Figure 2. SDF-1 induces migration of MK cells. (A) SDF-1 (200 ng/ml) or conditioned medium from the MS5 stromal cell line, which is known to
contain SDF-1, induced migration of 15–20% of MKs. Replacement of SDF-1 with TPO (100 ng/ml) and KL (100 ng/ml) failed to induce migration of
MKs (n 5 4, P ,0.05). Replacement of SDF-1 with other known chemokines and cytokines such as VEGF or bFGF at 100 ng/ml, IL-11 or IL-6 at
100–200 ng/ml, IL-8 (200 ng/ml), or other chemokines at 100–200 ng/ml, including the CXC (IL-8, NAP-2, IP10, and MIG) or CC chemokines
(MIP-1a, MIP-3a [LARC, Exodus-1], MIP-3b [ELC], RANTES, MCP-1, -3, and -5, 6Ckine/Exodus-2/secondary lymphoid tissue chemokine [SLC],
thymus-expressed chemokine [TECK], and PF4), also failed to induce migration of MKs (n 5 3, P ,0.01 for all experiments). (B) Addition of SDF-1 (200
ng/ml) to the lower chamber of the 5-mm transwell plates resulted in the migration from the upper chamber of 20% of ex vivo–expanded MKs (day 12).
Incubation of cells with pertussis toxin (2.5 mg/ml) resulted in complete blockage of migration of MKs. Addition of SDF-1 to the upper and the lower
chamber of transwells to disrupt the gradient resulted in complete abrogation of MK migration. Addition of heparin or mAb to CXCR4 (12G5, 40 mg/
ml) to the transmigration medium resulted in partial inhibition of migration of MKs (n 5 4, P ,0.05 for both heparin and 12G5). (C) SDF-1 at various
concentrations (50–1,000 ng/ml) was placed in the lower chamber of the transwell plates with MKs expanded for 14 d, and the number of CD41a1 cells
migrating through the 5-mm transwells was quantified by two-color flow cytometry. The ED50 for MKs is z125 pmol/liter (n 5 3).543 Hamada et al.
within the bone marrow may be less functionally active. In-
troduction of heparin significantly inhibited migration of
MKs (n 5 4, P ,0.05; Fig. 2 B), suggesting that binding of
SDF-1 to heparin reduces SDF-1 activity, creating a func-
tional gradient within the bone marrow microenvironment.
The ED50 for migration of CD41a1 MKs in response to
SDF-1 is z125 pmol/liter (n 5 3; Fig. 2 C). To determine
the relative amount of CXCR4 receptors expressed on the
surface of these cells, we performed SDF-1 ligand binding
studies on TPO/KL ex vivo–expanded immunomagnetic
purified MK cells. 125I-labeled SDF-1 displacement binding
studies revealed a dissociation constant (Kd) for SDF-1
binding to MKs of 17 6 5 nM (data not shown). By Scat-
chard analysis of the SDF-1 binding data, 2.14 3 105 re-
ceptors per cell were estimated. Collectively, the binding
and chemotaxis data suggest that SDF-1 is a potent
chemokine for mature MKs.
SDF-1–induced Transmigration of MKs through BMEC.
To explore the possibility that interaction between the
BMEC and mature MKs in response to SDF-1 may be crit-
ical for MK migration, ex vivo–expanded MKs were
placed in transwell plates coated with confluent monolayers
of BMEC. Subsequently, SDF-1 at 200 ng/ml was added
to the lower chamber. In the absence of SDF-1, there was
no migration or increased adhesion of MKs to BMEC.
However, in the presence of SDF-1, 14 6 3% of MKs mi-
grated through BMEC (n 5 5, P ,0.05; Fig. 3 A). Fur-
thermore, in the presence of SDF-1, there was a significant
increase in the adhesion of MKs to BMEC monolayers (n 5
5, P ,0.05; Fig. 3 A).
MK transmigration through IL-1b–stimulated BMEC is
dependent on E-selectin. To determine whether adhesion
molecules expressed on BMEC or MKs are critical for
transendothelial migration of mature MKs, ex vivo–
expanded MKs were placed in the upper chamber of tran-
swells coated with confluent monolayers of resting or IL-
1b–stimulated BMEC with and without blocking mAb to
various known inducible endothelial cell adhesion mole-
cules, including ICAM-1, VCAM-1, and E-selectin. Acti-
vation of BMEC monolayers with IL-1b resulted in a
threefold increase in the migration of MKs in response to
SDF-1 (n 5 4, P ,0.01; Fig. 3 B). Blocking mAb to endo-
thelial cell–specific adhesion molecule E-selectin, but not
VCAM-1 or ICAM1, blocked the migration of MKs by
50%, suggesting that cellular interaction of MKs with
BMEC monolayers is critical for the migration of MKs (n 5
5, P ,0.05). The addition of a combination of mAbs to
VCAM-1, ICAM-1, and E-selectin did not block the mi-
gration of MKs beyond that originally blocked by
E-selectin mAb (n 5 4, P .0.05; data not shown).
SDF-1 Induce Transendothelial Migration of Polyploid Ma-
ture MKs. Migration of MKs through BMEC was associ-
ated with profound morphological changes in MKs, in-
cluding unilateral pseudopodia formation (Fig. 4 A). Light
microscopy of the transmigrated Wright/Giemsa-stained
MKs showed a predominance of intact polyploid MKs, sug-
gesting that polyploid MKs preferentially express CXCR4
and migrate in response to SDF-1. Ploidy analysis of transmi-
grating MKs in response to SDF-1 (200 ng/ml) through the
5-mm pore showed preferential migration of polyploid (.2,
4, 8, and 16N; n 5 4, P ,0.05) MKs (Fig. 4).
Transmigration of MKs through BMEC in response to
SDF-1 results in formation of functional platelets. MKs that
migrated through BMEC monolayers in response to SDF-1
(200 ng/ml) showed rapid fragmentation into platelets. Flow
cytometry analysis of the CD41a1 platelets generated from
migrated MKs showed the typical forward and side scatter
pattern of in vivo–generated platelets (Fig. 5 A). In addition,
platelets generated from migrated MKs were functional since
they expressed P-selectin (CD62P) in response to thrombin
stimulation (Fig. 5 C). In addition, all migrated platelets
demonstrated strong expression of CXCR4 (Fig. 5 D).
Quantification of platelets derived from MKs migrated
either through bare transwells or BMEC monolayers in re-
sponse to SDF-1 demonstrated significantly higher num-
bers of platelets generated from MKs migrating through
Figure 3. SDF-1 induces transmigration of MKs through BMEC
monolayers. (A) Ex vivo–expanded MKs (day 12) were incubated in the up-
per chamber of the transwell plates coated with confluent monolayers of
resting inactivated BMEC. Introduction of SDF-1 (200 ng/ml) in the lower
chamber induced increased migration of MKs. In addition, SDF-1 increased
the affinity of MKs for BMEC monolayers. (B) Ex vivo–expanded MKs
were incubated in the upper chamber of 5-mm transwell plates coated with
IL-1b–treated BMEC monolayers, in the presence and absence of neutraliz-
ing mAbs to E-selectin, VCAM-1, and ICAM-1. IL-1b treatment of
BMEC results in a threefold increase in adhesion and a fourfold increase in
transmigration of MKs in response to SDF-1. mAb to E-selectin but not to
ICAM-1 or VCAM-1 resulted in significant inhibition of transmigration of
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BMEC monolayers (n 5 3, P ,0.05; Fig. 5 B). During this
period, there was no detectable platelet formation by MKs
that were not exposed to SDF-1. In addition, SDF-1 alone
without BMEC coculture did not enhance platelet forma-
tion, nor were nonmigrating MKs, exposed to SDF-1 but
remaining on the apical surface of BMEC monolayers, able
to produce any significant numbers of platelets. These data
suggest that interaction of MKs with BMEC in response to
SDF-1 is critical for induction of signaling pathways that
may induce generation of platelets.
Electron microscopy of the cells in the lower chamber of
the transwells recovered 3 h after transmigration in re-
sponse to SDF-1 showed the presence of large polyploid
MKs (Fig. 6 A), demonstrating that SDF-1 induces the
transendothelial migration of whole intact MKs. In addi-
tion, electron microscopy of cells in the lower chamber 12 h
after transendothelial migration demonstrated the presence
of MKs in the process of fragmentation into platelets (Fig.
6 B). These data demonstrate that SDF-1 induces rapid mi-
gration (3–5 h) of intact polyploid MKs through BMEC,
followed by fragmentation of MKs into platelets within
12–24 h after migration.
Discussion
Despite the discovery of TPO, the site and mechanism
of platelet formation are not well defined. Several lines of
evidence suggest that mature polyploid MKs have the ca-
pacity to transmigrate through BMEC and release platelets
within the bone marrow sinusoidal space or the lung capil-
laries. In search for chemokines that may induce transmi-
gration of MKs through BMEC, we have discovered that
mature polyploid MKs express the chemokine receptor
CXCR4. In response to SDF-1, MKs transmigrate through
bare transwells as well as BMEC monolayers. The ED50 for
the transmigration of MKs is 125 pmol/liter, suggesting
that SDF-1 is a potent chemotactic factor for human MKs.
Monocytes and lymphocytes have been shown to transmigrate
through endothelial cells in response to various chemokines,
including SDF-1, MCP-1, MIP-1a and b, and IL-8. How-
ever, among the known factors that may potentially influ-
ence MK function and induce chemotaxis, including TPO,
VEGF, KL, IL-6, IL-11, and myriad other CXC or CC
chemokines, only SDF-1 induced transmigration of MKs.
The majority of the transmigrated MKs were large poly-
ploid mature CD41a1CD42b1 MKs, suggesting that ex-
pression of CXCR4 by mature MKs may initiate cellular
signaling pathways that in turn initiate the process of mi-
gration and platelet formation. Interaction of MKs with
BMEC is critical, since adhesion molecules expressed on
the BMEC monolayers seem to play a crucial role in regu-
lating the migration of MKs through endothelial cell junc-
tions. Many studies have shown that BMEC in vivo assume
the phenotype of activated endothelium and constitutively
Figure 4. Ploidy analysis of migrated MKs. (A) Attachment of MKs to
BMEC results in profound morphological changes, including a unilateral
pseudopod formation (arrow). (B) Light microscopy of Wright/Giemsa-
stained transmigrated MKs in response to SDF-1 (200 ng/ml) demon-
strated a predominance of polyploid MKs. (C) Ploidy analysis of migrated
MKs in response to SDF-1 demonstrated a predominance of polyploid
MKs (n 5 4, P ,0.05 for 4, 8, 16, and 32N).545 Hamada et al.
express low levels of VCAM-1 and E-selectin (37). In ad-
dition, mature MKs are capable of producing physiological
levels of stimulatory cytokines, including IL-1b (38). In
this regard, in order to mimic the in vivo phenotype of
BMEC, BMEC monolayers were activated with IL-1b. Ac-
tivation of BMEC results in the upregulation of adhesion
molecules, including E-selectin, VCAM-1, and ICAM-1.
Activation of BMEC with IL-1b not only increased the
number of BMEC-bound MKs, it also significantly increased
the number of migrating MKs. In addition, migration of
MKs through activated BMEC was partially blocked by
neutralizing mAb to E-selectin, but not to VCAM-1 or
ICAM-1. This finding demonstrates that migration of MKs
is not a random process, and involves sequential interaction
of mature MKs with specific adhesion molecules on endo-
thelial cells. These series of events may facilitate egress of
MKs and initiate platelet release.
Blocking mAb to VCAM-1 and ICAM-1 did not signif-
icantly block the migration of MKs. Furthermore, a com-
bination of neutralizing mAbs to VCAM-1, ICAM-1, and
E-selectin did not block the migration of MKs beyond that
originally blocked by E-selectin mAb. E-selectin expressed
by activated endothelial cells seems to play a role in the teth-
ering of leukocytes. In addition, engagement of E-selectin
with its ligand has been shown to result in inside-out signal-
ing (39, 40). Therefore, it is possible that engagement of
E-selectin results in activation of signaling pathways that mo-
bilize MKs for migration.
Based on the data presented in this paper, z75% of day
12 to day 14–expanded MKs express CXCR4. IL-1b stim-
ulation of BMEC monolayers induces migration of up to
45 6 5% of the MKs. However, since close to 25% of
CXCR41 MKs do not migrate, it is possible that either an-
other factor is needed for migration or not all CXCR41
MKs express the appropriate adhesion molecules. There-
fore, based on these data we can infer that the mere func-
tional expression of CXCR4 on MKs is not sufficient for
migration, but that attachment through the appropriate ad-
hesion molecules or stimulation by an as yet unrecognized
chemokine is critical for transendothelial migration.
Although transmigration of MKs through bare transwells
or BMEC was rapid (3–5 h), platelet generation took place
maximally 24–48 h after migration. However, compared
with bare transwell plates, migration of MKs through
BMEC resulted in higher numbers of functional platelets,
suggesting that collective interaction of MKs with BMEC
and SDF-1 is critical for optimal platelet production.
However, both flow cytometric and electron micro-
scopic analyses of transmigrated MKs demonstrated that
even after 48 h, close to 20% of MKs remained intact,
without any indication of generating platelets. These data
suggest that CXCR4 may be expressed on polyploid MKs
at different stages of maturation. However, the more ma-
ture MKs will give rise to platelets immediately after migra-
tion, whereas the less mature may migrate and give rise to
platelets after the process of platelet compartmentalization
has been completed. Therefore, it is conceivable that these
relatively immature MKs, not having enough time within
the sinusoidal space to release platelets, may travel to the
lungs and stochastically release platelets in the lung capillaries.
SDF-1 induces a significant increase in the adhesion of
mature MKs to resting or activated endothelial cells, sug-
gesting that SDF-1 may either modulate the adhesion mol-
ecule repertoire in the MKs, or indirectly modulate endo-
thelial cell adhesion molecule expression. Recently it has
been shown that endothelial cells also express CXCR4
(41). However, to date we have been unable to demon-
strate that SDF-1 has any effect on the adhesion molecule
repertoire of BMEC. Therefore, it is likely that SDF-1 may
directly regulate adhesion molecule repertoire on MKs.
Figure 5. Generation of functional platelets by
migrated MKs. CD41a1 platelets generated from
day 12 ex vivo–expanded MKs migrating through
either bare transwells or BMEC monolayers in re-
sponse to SDF-1 (200 ng/ml) were collected, fixed
in 0.7% formalin, and immediately subjected to
flow cytometry. (A) Forward and log side scatter of
platelets generated from migrating MKs in response
to SDF-1 demonstrate a characteristic scatter profile
identical to that of in vivo–generated platelets. (B)
CD41a1CXCR41 platelets generated 24 h after the
migration of MKs were quantified by two-color
flow cytometry. Migration of MKs through BMEC
in response to SDF-1 results in significantly larger
numbers of platelets than that of MKs through bare
transwells. (C) Platelets generated in response to
SDF-1 and BMEC are functional and express P-selec-
tin (CD62P) after thrombin stimulation. (D) Virtu-
ally all platelets generated from migrating MKs ex-
press CXCR4.546 SDF-1 Induces Transendothelial Migration of Human Megakaryocytes
CXCR4 is a coreceptor for T-tropic HIV strains, and has
been shown to mediate HIV entry into T cells in the pres-
ence of CD4 (42, 43). It has also been demonstrated that the
mAb (12G5) directed to CXCR4 can inhibit HIV entry
into cells (33, 44, 45). Furthermore, some subsets of patients
with HIV infection have been shown to have profound
thrombocytopenia on initial clinical presentation. Soluble
gp120 from T-tropic HIV has also been shown recently to
induce apoptosis in human neurons or to be chemotactic for
T cells (J. Hesselgesser, unpublished data). Based on the data
presented here, it is possible that thrombocytopenia in pa-
tients with HIV may be due to direct entry of HIV into
MKs via CXCR4. It also conceivable that direct interaction
of soluble gp120 with CXCR4 on MK cells could induce
apoptosis. This may result in dysregulation of chemotaxis of
MKs and disruption of platelet production.
Based on our results, in order for SDF-1 to induce mi-
gration of mature MKs in vivo, SDF-1 concentration has
to be much higher within the sinusoidal space than in the
bone marrow microenvironment. In fact, most studies have
shown that SDF-1 is produced by bone marrow stromal
cells, including bone marrow fibroblasts such as the MS5
Figure 6. Electron microscopic analysis of MKs that have migrated
through BMEC. MKs migrating through BMEC monolayers were recov-
ered 12–24 h after the addition of SDF-1 (200 ng/ml) from the lower
chamber of the transwell plates, and were analyzed by electron micros-
copy. (A) A large intact polyploid MK that has maintained its morpholog-
ical integrity 3 h after transmigration through BMEC and 5-mm pores.
Original magnification: 34,000. (B) An MK 12 h after transmigration in
the process of platelet formation. Multiple distinct platelets (arrows) are
seen throughout the cytoplasm of the MK. Original magnification:
32,500.547 Hamada et al.
murine fibroblastic cell line (26). Given that heparin signif-
icantly blocked SDF-1 activity, it is conceivable that SDF-1
produced within the bone marrow microenvironment,
particularly in the vicinity of the BMEC, is functionally
inactive. Therefore, assuming that SDF-1 within the sinu-
soidal space may exist in an unbound form, this could pro-
duce a functional gradient resulting in selective migration
of MKs from the bone marrow microenvironment to the
sinusoidal space.
On average, on day 12 of ex vivo expansion, 57 6 5% of
cells derived from expansion of CB CD341 cells in the
presence of TPO and KL were MKs expressing CD41a1
cells. We have tried to purify MKs from ex vivo–expanded
cells by flow cytometric cell sorting or elutriation. How-
ever, given the fragile nature of polyploid MKs, any ma-
nipulation of ex vivo–expanded MKs results in significant
loss of mature polyploid MKs. In addition, we have found
that in contrast to CD341, T, or dendritic cells, minor
physical manipulation of MKs by multiple centrifugation
results in random disintegration into platelet-like particles,
nonspecific calcium fluxes, and loss of response to SDF-1.
Therefore, in the experiments described in this paper, we
have used day 12 to 14 ex vivo–expanded MKs with mini-
mal physical manipulation. This step has remarkably en-
hanced the yield of intact viable MKs that can effectively
be used in migration studies.
Our data suggest that MKs may release platelets during
transmigration through BMEC or after exiting through
BMEC. SDF-1 induces transendothelial migration of MKs,
suggesting that MKs have the capacity to release platelets
during transmigration or after exiting the bone marrow.
Therefore, expression of CXCR4 by mature MKs may be
the critical cellular signal for transmigration of MKs and plate-
let formation. The cellular signaling pathways activated as the
result of transendothelial MK migration that may mediate
platelet formation are the subject of ongoing experiments.
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